I believe a little research will show GNBT did complete a fairly large Phase III trial of it's RapidMist Ora-lyn spray for diabetics and did file for approval with the FDA some years ago. GNBT said after that filing the FDA requested additional data and a reformulation of the compound to increase its strength and reduce the number of sprays required to deliver the appropriate dose. For awhile GNBT provided a couple of updates on how that reformulation was going, but I haven't seen an update in several years. There was one which said the stronger formulation had been successfully tested in primates, but that was the last I ever saw. I suspect they ran out of money to work on it?

As to the whole India story, that is apparently in the hands of Shreya. GNBT has nothing to do with it (unless they ask the partner for a progress report now and then or something.) Whether Shreya is actively working on it, I do not know. They were supposed to be doing a test of the Ora-lyn compound in India the last I saw.....

It is interesting, though, I don't recall any mention of all this on the CC....does anyone??

I think the new O/S is about 908K, but I think your guess at the "float" would be high. I believe about 350K-400K is the number.

The last report I saw which listed large shareholders contained about 12 names and they owned about 60-65% of the Shares (including Joe, of course!) Their average cost is way, way above the current trading range. In fact, the lowest cost would be about $15 on todays stock, most of the ownership is at much higher levels even than that.

The question is, what are they looking for out of this puppy? Any deal Joe puts together is going to need support from most of those holders. I have no idea how he is going to do it, but he must have a plan. He just sank another $500,000 into the company, which has now been turned into a convertible note.

It's going to be interesting to watch....

I'm not sure I know the answer, maybe someone else could weigh in. I do know they want to get the stock above that "magic" $5.00 level to make it more attractive to institutional investors and to help qualify for a listing on an exchange.

The problem with the listing aspect is there are additional requirements for a listing such as earnings, profitability, history, net worth, etc. Not all may be required by all exchanges and the requirements differ (you could research that) but it is not strictly stock price.

As to raising money, I guess a $8.00 or $9.00 stock looks better to a potential partner, but that alone is not going to do it. Any such investor would certainly know the history of GNBT and it got up to that price, and it has no effect whatsoever on the underlying fundamentals for the company.

So, in a nutshell, like I said, I'm not sure what good the R/S will do.

What will help the stock price go up and stay up is some actual news about one of their products or technologies or patents or something. That is always what they have needed and been unable to produce.

Yes, but there are some big "ifs" there.

Any approval for the sickle cell drug, if it comes, is months away. And to finalize the merger, GNBT needs some money. Soon. I believe it was by mid-March, something like $2.5 myn maybe? We need something really good to happen, real soon. I'm not saying a miracle or anything, but some good karma or maybe legerdemain would help!

I suspect the weakness in the stock ever since the CC is almost entirely due to apprehension over the pending 1:1,000 reverse stock split. Other than that, there were some positive aspects to the CC,

Current holders (especially traders) are willing to jump the ship at any sign of a rally because they are so afraid of that split. And I also suspect that no potential new investor is willing to buy into a stock facing such a draconian measure. Possibly GNBT management will recognize this fact and rethink the announced approach, but there is no sign of that happening so far.

There is one thing about the split that intrigues me somewhat. After such a split, there would be roughly just 1,000,000 shares of GNBT outstanding. Of that, about 60-65% is held by just about a dozen or so large and presumably longer-term investors (as reported by GNBT in its financial statements.)

That means the available float for trading each day would be around 350,000 shares, which could lead to a really volatile environment!

That would be nice, but it's going to take some really big volume to achieve that. I would say 20-30 myn shares maybe.....And it's got to stay above a penney for a few days, too, if it's going to mean anything....

Regarding this reverse split matter, the 10-K also includes the following paragraph:

"Our stockholders approved a reverse split proposal at our annual general meeting held on August 19, 2015, which approval allows the Board to implement a
reverse split in its discretion at any time prior to December 31, 2016 and is not contingent upon listing our common stock on a national stock exchange. However,
the terms of the securities purchase agreements that we entered into on January 14, 2014, March 27, 2014 and June 24, 2015 prohibit us from undertaking a reverse
or forward stock split or reclassification of our common stock except for a reverse stock split made in conjunction with a listing of the common stock on a national
securities exchange."

This would seem to exclude any arbitrary "overnight" decision by management to effect any reverse split without receiving an approval or amendment to those security purchase agreements referenced.

Regarding the takeover or acquisition theory, I am not saying it's impossible, but I would note that more than 60% of Generex stock is held by about a dozen large investors. It would seem necessary to have them, or at least most of them, to buy into the terms and price of any such proposal.

As to the Yahoo allegation, you have me confused with someone else. I have never posted to the Yahoo board, I don't use Yahoo, don't even have a Yahoo account.....At least I didn't get hacked this last time!

Thanks for the pointer. I checked out their website, they do mention the "RapidMist" deliver system and say they have a license for it. That's the Generex technology. So there is truth to that story....

We'll see if anything comes from it!

I wonder if the following will have any impact on Generex? You may recall they signed a deal last year I believe with a Canadian company to explore the possibilities of delivering measured doses of cannabis using their Ora-lyn spray technology.

We need something to wake this puppy up.....

http://www.msn.com/en-us/money/markets/canada-gets-green-light-on-legalizing-pot-with-retail-sales/ar-AAlwlms

Please think about it....The Generex warrants by themselves are not marketable, they must be converted to common stock through exercise. To do that the warrant holders must pay Generex some money. Not a lot in some cases, but something. And the exercise of warrants is a reportable action by Generex.

Another thing to think about, a lot of the warrants outstanding are worthless at current market prices. The latest report shows some warrants with exercise prices above $1.00 and many of them at %.50---.80 etc. No one is going to exercise those to sell at $.015.

I didn't say anything about "big pharma" being interested or even whether I thought the stock was cheap. Obviously from the price action a lot of people don't think it's cheap enough yet....

All I was doing was pointing our that AE-37 itself and the Phase II Trial were real. The Trial was sanctioned by the FDA and the details were available through the FDA website. The doctors and hospitals participating were real and the patients participating were real. That's all I was pointing out. It is not a fabrication as some posters will try and claim over and over again.

Whether that ever makes Generex worth anything is an entirely different matter.

Just FYI, the Generex Phase II Trial was a rather large number of patients for a Phase II study. Somewhat in excess of 300 I believe. Probably about 1/2 would have received the vaccine and 1/2 a placebo.

Enrollment in the Trial is closed, but some patients are still receiving the vaccine. You can follow their discussions about it on some of the cancer support message boards.

And the poster who said Generex had no money to continue operations, that is not quite correct. The 10-Q showed some 2+ million cash on hand. Not a lot, but enough to pay the light bill for a few months I would think. Obviously they will need a lot more cash and partner for support if they are to survive and proceed to a Phase III Trial.

Somedays he forgets to take his medication.....He was gone for awhile this summer and this board was so much nicer....

The announcement is interesting, though hardly a major development. Apparently they are just "talking" about a collaboration and have not signed an actual deal yet. Also, it sounds like the Canadian company is another start-up, similar to GNBT, with no real products or customers yet....

Still, I've seen the magic word "cannabis" work wonders in other places, so the action bears watching the next few days. A close well above the .02 price for a few days might mean the stock has put in a bottom...

You are correct as to what the original proposal was. And it seemed like a sensible idea, it might have worked at that time. However, Generex choose not to do it for whatever reason, and now the stock has fallen our of bed.

With the stock hovering about the $.02 area, they are really in a bind. At that level, the company market cap is negligible. A reverse split is useless....even a 1-100 reverse would only yield a $2.00 stock (temporarily) and that is not good enough to qualify for a listing anywhere, not to mention all the other shortcomings Generex would have to overcome about its net worth, working capital, retained earnings, etc.

The only hope is for Generex to have some positive news. Not a press release, not another white paper, not another conference. Some real news, say about an AE-37 partnership or approval for Ora-lyn in India, something like that.

That might be enough to get the stock up to a respectable valuation, I am not sure. I believe it is the only hope....

I suppose there is always the possibility at any time for a surprise, but I've neither seen nor heard of anything on AE-37 that is pending.

The only thing I am currently awaiting is an update on Ora-lyn in India. They said last spring that 2 Generex executives would be traveling to India this summer to meet with the drug approval committee down there. I've not seen anything further on that plan since the announcement.

Yes, it is quieter without "Mr. Crazy"

Sorry, but you are the one who has no clue as to what we are talking about. I'm not trying to "pump" or "dump" anything. I have no dog in this fight at the moment.

All I was doing was reporting what I saw. I have a trading app from my broker which runs a consolidated ticker tape of stocks I select all day long. The app also records every trade reported on that tape all day.

At 4:00 PM when I checked the data, my app was showing the last trade in GNBT to be 1,000 shares at .0287 at 3:51 PM. The total vol for the day was about 3.95 MYN shares. Now if you look at the official closing data for Friday, say on CNN Money, you see the stock reported at .032 and the vol at 4.059 MYN. Their chart also ahows a sharp spike in the price in the last moments of trade.

That's all I'm reporting, no more, no less. There may be an error somewhere, the data I see may be incorrect, who knows without checking with the NASD? But I can read and comment on what I see.

So please, once again, go away and leave the rest of us in peace....

I don't think "grobtek...." whoever he or she is will opine on anything reasonable for discussion. He or she is a very disturbed individual. I think he/she has written a computer script to post some garbage to this board at random intervals just to irritate the rest of us.

I find the close on our little stock interesting today. Looks like someone bought about 100M or so shares at .032 right on the close. I never saw the trade print on my tape, but the closing price and volume has been adjusted to reflect it. At least we didn't sink to the bottom of the well today....

I think there has to be some sort of a little "pop" in this stock when the AE-37 Phase II Trial results are presented publicly and discussed at the ASCO Conference. It may not last, but I do not think it will be totally, absolutely ignored......

I saw today that Pfizer is going to proceed with asking for FDA approval for a new cancer drug based on its Phase II Trial results because they were so promising. They do not want to wait to run a Phase III Trial....

The final results for the AE-37 Phase II Trial which are to be released for the ASCO Conference and then presented to the meeting will not be "bad." Generex published the preliminary results late last year and then , in February I believe, announced that the final results were "consistent" with the "preliminary results previously released." This was at the time they announced their selection as an ASCO presenter.

So the big issue now is not "what are the results?" but how are they received? Will the impression on reviewers, analysts, peers, etc., be favorable? Will these folks say good things about the results? That's what you want to be looking for!

I believe the ASCO conference is the first week in June. Generex will be a presenter at that conference, it has already been announced.

I believe the "synopsis" or "highlights" of that presentation will be available soon, probably next week.

Don't pay much attention to "gross...." whoever he is, he lives in a different universe. Sometimes he is the only participant on this board for days, he talks to himself, too.

I have no comment on the humor one way or another, but thought I would point out that if Ora-lyn were to be approved in India, the patients paying for it is not a big problem. India has a system of what is essentially socialized medicine, and the government pays most of the cost for drugs approved and legally prescribed in India. I should also point out that the government has a say in how that drug is priced and must approve the pricing.

My screen shows a bid for 1.2 myn shares at 0353. Does anyone else see that?

I have found the selling in the past few days to be puzzling. It must be smaller short-term flippers who want to go somewhere else for action? Anyone have any thoughts?

It is public knowledge that they will be featured at ASCO when they release the AE-37 Phase II Trial results, so that is good news on the horizon. Although we haven't hear anything from India in several months, that could also pop up any day.

There's always the "bankruptcy tomorrow" crowd over on Yahoo, but GNBT has plenty of cash on hand to survive awhile longer. They got about $2.5 myn from exercise of warrants in their 4th quarter and another $2.5 myn from the recent financing. Say what you want about all the dilution coming, they are not going to run out of cash right away.

I guess that's possible, but there still should be some buying from sources (India, offshore, institutions, someone....) who knows the news. As far as I know, they would not be violating any securities laws if the info has been publicly released in India....

I also spent some time chasing that and found nothing conclusive. I am still puzzled by that website in India www.mydigitalfc.com which published the "announcement." It appears to be a perfectly legitimate site and the time/date stamp on the site is current everyday in Mumbai local time. How then was a hacker/spoofer/promoter able to post a "fraudulent" announcement from Shreya?

Why, then, have we heard nothing from Generex? Can it be that they are this far behind in communications with their Indian representative? That also seems unlikely.....

Sorry, I misinterpreted the post I replied to. I thought the implication was Seahawk and friends would dump their stock after hours on this little move, now....Yes, when it was NASDAQ listed it could trade pre-market and after-hours.

Just to clear up one error in your post, there is no "after hours" trading in OTC BB and Pink Sheet stocks. Those trades you see hit the tape after 4:00 PM are "Form T" trades which occurred at some point during the trading day and the broker-dealer is "catching up" his books for reporting purposes. They weren't necessarily a single trade, either. Trades not reported at trade time during the day can be aggregated for "Form T" reporting purposes. This is in accordance with SEC rules.

And BTW, it looks like your favorite foil Joe Moscato of Seahawk has had ample chance to take his "loan shark" penney profit today. The 13-G filing on February 7 registered 1,066,667 of his shares for sale. Volume today was almost 5 MYN, so guess Joe's out.......

I generally agree with you, although there are always those exceptions...look what Denderon did before it finally crashed and burned. Sarepta and Seattle Genetics have also defied gravity so far....

There is one interesting thought on the financing thing. I've done a little research on those recent SEC filings. There is not a lot of that stock which is covered by the so-called "free shares" that everyone gripes about. If those holders were so inclined, they could have sold a lot of that just today....there were 4MYN shares reported as "Form T" trades after the close at about .0350

Most of the stock covered by those filings must be acquired by the exercise of options at .03 or conversion of preferred stock. I still refuse to believe that those holders would be content to exercise at .03 and sell at .035. I think they would be looking for a much better return than that! I would be more worried about them if GNBT ever gets to .10 or .12 a share.

And one final thought....if they do exercise, Generex gets some cash to finance itself for awhile without further dilution.....

Anybody have any thoughts on this?

The preliminary analysis of the Phase II AE-37 Trial results which they reference in this announcement were quite encouraging. I believe those were available early last Fall. And you are correct about the sample size, 300+ patients is quite large for a Phase II Trial.

The chart is very hard to read, but I have found that my charts are somewhat less than reliable sometimes when dealing with these biotechs, particularly low-priced, speculative ones.....The moves which can be generated---good or bad---by a single piece of news or data can really mess with the tried and true ideas of the charts!

I believe the rules of ASCO require the "embargo" of the final data pending the ASCO presentation, so don't blame Generex for that delay. It does mean that if you are a bull on GNBT you are going to have a long wait for any more bump from AE-37!! Unless they come up with a partner in the interim.....???

While we are waiting, an update on the status of Ora-lyn in India would be nice....

You need to get more than a life, fella, you need to get help.....

You need to get a life.....I didn't say one word about whether GNBT was a good investment or not. I have no idea where the stock is going. I am not interested in pumping or dumping anything.

I just pointed out the known facts about the AE-37 Trial and the organizations and people involved with it. You don't seem to have a lot of use for facts....

You are entitled to view the world anyway you want. Let's just leave it at that.

If past is prologue, you are likely right. GNBT has a long history of disappointing on promised delivery dates of various kinds. And there certainly is nothing legally binding about failing to make a projected date for a predicted announcement.

I will say as a positive about GNBT. I do not believe it is a "SCAM" as so many bashers over on the YMB claim every day! Over and over, BTW, same posts, same ignorant assertions, same baloney....

Whether AE-37 is eventually successful remains to be seen, but it certainly does exist. There is an official FDA website which tracks the development process. It was updated recently. The names of the institutions and physicians associated with the trail are real and none of them have ever complained about their names being used falsely. The AE-37 trial is mentioned often on the blogs for cancer support groups. Patients talk about the treatment and where they go to receive it and what their personal results have been.

So whether it is good or bad as a cancer treatment has yet to be proven, but it is not a "SCAM."

You are certainly entitled to your opinion, I just don't agree. The "loan sharks" assessment may apply to some, but I doubt it makes up any significant portion of those investors.

Until very recently, this stock was trading 2-3 myn shares all day. Okay, we've seen a few 20-30 myn shares/day recently. But if your "loan sharks" exercise those warrants and convert the preferred, do you think they can sell 60+ myn shares at $.04 or $.05 quickly. And to whom? Other "loan sharks" who then plan to sell 60+ myn shares at $.06?

You are not being logical.

Clarifying the S-1 posted Friday, Jan 24....

Generex did not "sell" any new shares. The shares covered by the S-1 are issuable under warrants and preferred stock which was actually placed with certain investors last summer (July, as I recall.) At the time of that placement, those investors paid Generex about $1.2 myn for the warrants and preferred stock.

The investors are simply registering the shares covered by those warrants and the preferred stock which they already own for possible future sale. In the case of the warrants, should they choose to exercise and sell, they will have to pay Generex $.03 per share to get the stock. (yes, there are ways to sell the shares prior to exercise by shorting them versus the collateral of the warrants, but they would still eventually have to exercise the warrants to get the actually stock to cover the short position.)

It seems unlikely to me that such large investors, whoever they may be, are in this business to buy a stock for $.03 and then sell it for $.04 or $.05. Even with 60+ myn shares, there is not a lot of profit in that. I suspect they are looking for something significantly higher.

I would be interested in other opinions about that.

It certainly has been acting better the past few weeks, like someone knows or thinks they know some good news is on the horizon. Of course they have telegraphed that the AE-37 Phase II Trial results are encouraging and they have stated those results will be available this month. I just hope they keep that promise. GNBT has had a history of falling short on promises......It would not be good for them to delay that release for some reason!

There was a trade of 1MYN shares at .0304 at 15:49:03 that is not showing up in the days total volume of 2,338,979. There was another trade of 429,815 shares at the same price 30 seconds later. That trade seems to be included in the days volume total.

Sorry, maybe my post was not clear. There was no "transaction." The bid size on the market was showing 1 MYN to buy at .0278. That shortly grew to a total bid of almost 1.3 MYN.

In the last hour of trade, that buyer(s( actually got about 150K shares, that was all. No large trades at .0278 in the last hour.

There is a "bid" for a little more than 700K this morning at .0275. I don't know if it means anything at all, but someone wants to buy some GNBT....

At about 2:45 PM today, I see a bid for 1 MYN GNBT at .0278....can anyone verify? Be interesting to see if they get the stock.....

You don't drink Ora-lyn. You don't inhale it, either. You spray it into your cheek inside your mouth and it is absorbed through the membranes inside your mouth.

This has been an ongoing misunderstanding ever since GNBT began working on Ora-lyn despite the company's numerous attempts to clarify.

One thing which has always interested me and many others I know in the medical community is the technology itself. IF it works safely and is reliable, what other possibilities for other drugs might exist? GNBT holds the patents for this technology.